ID   PC-9
AC   CVCL_B260
SY   PC9; PC-9/S1; PC-9S1
DR   BTO; BTO:0005518
DR   CLO; CLO_0050067
DR   EFO; EFO_0002847
DR   BCRJ; 0331
DR   BioSample; SAMN03470946
DR   BioSample; SAMN10989619
DR   CCLE; PC9_LUNG
DR   Cell_Model_Passport; SIDM00236
DR   ChEMBL-Cells; CHEMBL3307867
DR   ChEMBL-Targets; CHEMBL614102
DR   Cosmic; 713867
DR   Cosmic; 801574
DR   Cosmic; 876137
DR   Cosmic; 897746
DR   Cosmic; 911753
DR   Cosmic; 915329
DR   Cosmic; 917985
DR   Cosmic; 929156
DR   Cosmic; 946058
DR   Cosmic; 1001658
DR   Cosmic; 1002731
DR   Cosmic; 1047092
DR   Cosmic; 1128254
DR   Cosmic; 1146943
DR   Cosmic; 1239896
DR   Cosmic; 1336875
DR   Cosmic; 1571735
DR   Cosmic; 1656893
DR   Cosmic; 1731370
DR   Cosmic; 1745414
DR   Cosmic; 2015224
DR   Cosmic; 2125285
DR   Cosmic; 2668307
DR   DepMap; ACH-000779
DR   ENCODE; ENCBS177ANS
DR   ENCODE; ENCBS480XRH
DR   ENCODE; ENCBS761VSF
DR   ENCODE; ENCBS987JQH
DR   GEO; GSM434290
DR   GEO; GSM481160
DR   GEO; GSM784274
DR   GEO; GSM794406
DR   GEO; GSM827407
DR   GEO; GSM1374821
DR   IARC_TP53; 2385
DR   IGRhCellID; PC9GEO
DR   LINCS_HMS; 50038
DR   LINCS_LDP; LCL-1630
DR   PRIDE; PXD001548
DR   PRIDE; PXD002224
DR   RCB; RCB4455
DR   Wikidata; Q54938469
RX   DOI=10.5795/jjscc.24.451;
RX   PubMed=1737336;
RX   PubMed=1847845;
RX   PubMed=4094096;
RX   PubMed=9023415;
RX   PubMed=9178645;
RX   PubMed=11005564;
RX   PubMed=11078804;
RX   PubMed=16105816;
RX   PubMed=17332333;
RX   PubMed=17511773;
RX   PubMed=19472407;
RX   PubMed=19799608;
RX   PubMed=20215515;
RX   PubMed=22313637;
RX   PubMed=23733853;
RX   PubMed=26202522;
RX   PubMed=26554430;
RX   PubMed=28196595;
RX   PubMed=28290473;
RX   PubMed=31068700;
WW   http://tcpaportal.org/mclp/
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: MD Anderson Cell Lines Project.
CC   From: Immuno-Biological Laboratories (IBL); Tokyo; Japan.
CC   HLA typing: A*02:06,24:02; B*07:02,55:02; C*03:03,07:02 (PubMed=9178645).
CC   Sequence variation: EGFR p.Glu746_Ala750del (c.2235_2249del15) (PubMed=16105816; PubMed=17332333; DepMap).
CC   Sequence variation: Homozygous for TP53 p.Arg248Gln (c.743G>A) (CCLE).
CC   Omics: Deep exome analysis.
CC   Omics: Deep membrane proteome analysis.
CC   Omics: Deep phosphoproteome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Derived from metastatic site: Lymph node.
ST   Source(s): PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 8
ST   D16S539: 9
ST   D18S51: 15
ST   D19S433: 13,15.2
ST   D21S11: 30
ST   D2S1338: 19,20
ST   D3S1358: 16
ST   D5S818: 11
ST   D7S820: 10,11
ST   D8S1179: 11,15
ST   FGA: 23
ST   Penta D: 13
ST   Penta E: 11
ST   TH01: 7
ST   TPOX: 11
ST   vWA: 17
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Male
AG   45Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 06-09-19; Version: 25
//
RX   DOI=10.5795/jjscc.24.451;
RA   Tsumuraya M., Nakajima T., Terasaki T., Kodama T., Shimosato Y.,
RA   Higuchi H., Uei Y.;
RT   "Analysis of LDH isoenzyme patterns in cell lines of the small cell
RT   carcinoma (lung) and retinoblastoma.";
RL   Nihon Rinsho Saibo Gakkai Zasshi 24:451-456(1985).
//
RX   PubMed=1737336;
RA   Yoshino I., Yano T., Murata M., Ishida T., Sugimachi K., Kimura G.,
RA   Nomoto K.;
RT   "Tumor-reactive T-cells accumulate in lung cancer tissues but fail to
RT   respond due to tumor cell-derived factor.";
RL   Cancer Res. 52:775-781(1992).
//
RX   PubMed=1847845; DOI=10.1007/BF00685110;
RA   Sasaki Y., Shinkai T., Eguchi K., Tamura T., Ohe Y., Ohmori T.,
RA   Saijo N.;
RT   "Prediction of the antitumor activity of new platinum analogs based on
RT   their ex vivo pharmacodynamics as determined by bioassay.";
RL   Cancer Chemother. Pharmacol. 27:263-270(1991).
//
RX   PubMed=4094096;
RA   Lee Y.-C., Saijo N., Sasaki Y., Takahashi H., Sakurai M., Ishihara J.,
RA   Hoshi A., Chen K.-M., Hamburger A.W.;
RT   "Clonogenic patterns of human pulmonary adenocarcinoma cell lines (PC-9,
RT   PC-13 and PC-14) and how they influence the results of test for
RT   chemosensitivity to cisplatin in the human tumor clonogenic assay.";
RL   Jpn. J. Clin. Oncol. 15:637-644(1985).
//
RX   PubMed=9023415; DOI=10.1006/cimm.1996.1062;
RA   Seki N., Hoshino T., Kikuchi M., Hayashi A., Itoh K.;
RT   "HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating
RT   lymphocytes of patients with non-small cell lung cancer.";
RL   Cell. Immunol. 175:101-110(1997).
//
RX   PubMed=9178645; DOI=10.1006/cimm.1997.1108;
RA   Nakao M., Sata M., Saitsu H., Yutani S., Kawamoto M., Kojiro M.,
RA   Itoh K.;
RT   "CD4+ hepatic cancer-specific cytotoxic T lymphocytes in patients with
RT   hepatocellular carcinoma.";
RL   Cell. Immunol. 177:176-181(1997).
//
RX   PubMed=11005564; DOI=10.1038/sj.neo.7900094;
RA   Kohno T., Sato T., Takakura S., Takei K., Inoue K., Nishioka M.,
RA   Yokota J.;
RT   "Mutation and expression of the DCC gene in human lung cancer.";
RL   Neoplasia 2:300-305(2000).
//
RX   PubMed=11078804; DOI=10.3892/ijo.17.6.1187;
RA   Takenaka K., Shibuya M., Takeda Y., Hibino S., Gemma A., Ono Y.,
RA   Kudoh S.;
RT   "Altered expression and function of beta1 integrins in a highly
RT   metastatic human lung adenocarcinoma cell line.";
RL   Int. J. Oncol. 17:1187-1194(2000).
//
RX   PubMed=16105816; DOI=10.1158/0008-5472.CAN-05-0331;
RA   Nagai Y., Miyazawa H., Huqun X., Tanaka T., Udagawa K., Kato M.,
RA   Fukuyama S., Yokote A., Kobayashi K., Kanazawa M., Hagiwara K.;
RT   "Genetic heterogeneity of the epidermal growth factor receptor in
RT   non-small cell lung cancer cell lines revealed by a rapid and
RT   sensitive detection system, the peptide nucleic acid-locked nucleic
RT   acid PCR clamp.";
RL   Cancer Res. 65:7276-7282(2005).
//
RX   PubMed=17332333; DOI=10.1158/0008-5472.CAN-06-3339;
RA   Okabe T., Okamoto I., Tamura K., Terashima M., Yoshida T., Satoh T.,
RA   Takada M., Fukuoka M., Nakagawa K.;
RT   "Differential constitutive activation of the epidermal growth factor
RT   receptor in non-small cell lung cancer cells bearing EGFR gene
RT   mutation and amplification.";
RL   Cancer Res. 67:2046-2053(2007).
//
RX   PubMed=17511773; DOI=10.1111/j.1349-7006.2007.00507.x;
RA   Fukuyama T., Ichiki Y., Yamada S., Shigematsu Y., Baba T., Nagata Y.,
RA   Mizukami M., Sugaya M., Takenoyama M., Hanagiri T., Sugio K.,
RA   Yasumoto K.;
RT   "Cytokine production of lung cancer cell lines: correlation between
RT   their production and the inflammatory/immunological responses both in
RT   vivo and in vitro.";
RL   Cancer Sci. 98:1048-1054(2007).
//
RX   PubMed=19472407; DOI=10.1002/humu.21028;
RA   Blanco R., Iwakawa R., Tang M., Kohno T., Angulo B., Pio R.,
RA   Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M.;
RT   "A gene-alteration profile of human lung cancer cell lines.";
RL   Hum. Mutat. 30:1199-1206(2009).
//
RX   PubMed=19799608; DOI=10.1111/j.1349-7006.2009.01351.x;
RA   Kuroda K., Takenoyama M., Baba T., Shigematsu Y., Shiota H.,
RA   Ichiki Y., Yasuda M., Uramoto H., Hanagiri T., Yasumoto K.;
RT   "Identification of ribosomal protein L19 as a novel tumor antigen
RT   recognized by autologous cytotoxic T lymphocytes in lung
RT   adenocarcinoma.";
RL   Cancer Sci. 101:46-53(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=22313637; DOI=10.4161/cbt.19238;
RA   Takata M., Chikumi H., Miyake N., Adachi K., Kanamori Y., Yamasaki A.,
RA   Igishi T., Burioka N., Nanba E., Shimizu E.;
RT   "Lack of AKT activation in lung cancer cells with EGFR mutation is a
RT   novel marker of cetuximab sensitivity.";
RL   Cancer Biol. Ther. 13:369-378(2012).
//
RX   PubMed=23733853; DOI=10.1101/gr.152322.112;
RA   Jia P., Jin H., Meador C.B., Xia J., Ohashi K., Liu L., Pirazzoli V.,
RA   Dahlman K.B., Politi K., Michor F., Zhao Z., Pao W.;
RT   "Next-generation sequencing of paired tyrosine kinase
RT   inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines
RT   identifies spectrum of DNA changes associated with drug resistance.";
RL   Genome Res. 23:1434-1445(2013).
//
RX   PubMed=26202522; DOI=10.1021/acs.jproteome.5b00477;
RA   Kitata R.B., Dimayacyac-Esleta B.R., Choong W.-K., Tsai C.-F.,
RA   Lin T.-D., Tsou C.-C., Weng S.-H., Chen Y.-J., Yang P.-C., Arco S.D.,
RA   Nesvizhskii A.I., Sung T.-Y., Chen Y.-J.;
RT   "Mining missing membrane proteins by high-pH reverse-phase stagetip
RT   fractionation and multiple reaction monitoring mass spectrometry.";
RL   J. Proteome Res. 14:3658-3669(2015).
//
RX   PubMed=26554430; DOI=10.1021/acs.analchem.5b03639;
RA   Dimayacyac-Esleta B.R., Tsai C.-F., Kitata R.B., Lin P.-Y., Choong W.-K.,
RA   Lin T.-D., Wang Y.-T., Weng S.-H., Yang P.-C., Arco S.D., Sung T.-Y.,
RA   Chen Y.-J.;
RT   "Rapid high-pH reverse phase stagetip for sensitive small-scale
RT   membrane proteomic profiling.";
RL   Anal. Chem. 87:12016-12023(2015).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P.,
RA   Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=28290473; DOI=10.1038/srep44021;
RA   Wang Y.-T., Pan S.-H., Tsai C.-F., Kuo T.-C., Hsu Y.-L., Yen H.-Y.,
RA   Choong W.-K., Wu H.-Y., Liao Y.-C., Hong T.-M., Sung T.-Y., Yang P.-C.,
RA   Chen Y.-J.;
RT   "Phosphoproteomics reveals HMGA1, a CK2 substrate, as a drug-resistant
RT   target in non-small cell lung cancer.";
RL   Sci. Rep. 7:44021-44021(2017).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//